ABLi Therapeutics

ABLi Therapeutics is a private, preclinical-stage biotech founded in 2016 and based in Cambridge, USA. The company is pioneering a novel approach to treating neurodegenerative diseases by targeting c-Abl kinase, a protein implicated in the initiation and progression of Parkinson's disease. Using its proprietary RAMP™ platform, ABLi aims to develop brain-penetrant, selective kinase inhibitors that could offer disease-modifying benefits. Its lead candidate, risvodetinib, is positioned to break the cycle of neurodegeneration and neuroinflammation in Parkinson's.

Proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) engine. It re-engineers kinase inhibitors using clinically validated data to create novel small molecules with enhanced brain penetration, higher potency, and improved safety for chronic use in neurological diseases.

ABLi competes in the crowded Parkinson's disease therapeutic landscape, which includes companies pursuing alpha-synuclein, LRRK2, GBA, and other targets. Its direct competition is limited but growing, as other groups investigate c-Abl inhibitors (e.g., nilotinib repurposing efforts). Its differentiation lies in the RAMP™ platform designed specifically for CNS-optimized kinase inhibitors.